Eli Lilly’s Omvoh achieves comprehensive disease control in 27.7% of ulcerative colitis patients at one year

Eli Lilly announced Oct. 15, 2026, that new Omvoh analyses showed corticosteroid-free disease control in ulcerative colitis and Crohn's disease at one year. Omvoh outperformed placebo on combined disease-control measures, including among patients with prior biologic treatment failure. Patients achieving these outcomes were more likely to report improved quality of life. The post hoc LUCENT and VIVID analyses will be presented at United European Gastroenterology Week 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via (Ref. ID: 202610150800PR_NEWS_USPR_____DE72063) on October 15, 2026, and is solely responsible for the information contained therein. (C)